A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

Recruiting

mRNA COVID-19 VaccineA Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

Sponsor:

Moderna

Code:

NCT06585241

Conditions

SARS-CoV-2

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Accepted

Interventions

mRNA-1273 Variant-containing Formulation

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-22. This information was provided to ClinicalTrials.gov by ModernaTX, Inc. on 2026-03-10.